摘要
目的探讨甲状腺肿瘤中CD44v6、趋化因子受体4(CXCR4)的表达及意义。方法免疫组化检测200例甲状腺癌(淋巴结转移阳性100例)以及20例甲状腺腺瘤中CD44v6和CXCR4的表达。结果甲状腺癌组CD44v6及CXCR4的阳性表达率分别为72%和69%,显著高于甲状腺良性腺瘤组的20%和15%;淋巴结转移组CD44v6和CXCR4表达的阳性表达率分别为88%和91%,显著高于无转移组的56%和47%;不同病理类型、临床分期和生存期甲状腺癌中CD44v6和CXCR4的阳性表达率显著不同。结论CD44v6及CXCR4在甲状腺良恶性肿瘤的鉴别诊断,甲状腺癌淋巴结转移与否的判断和预后估计等方面有重要意义。
Objective To investigate the expression and significance of D44V6, CXCR4 in thyroid neoplasm. Methods The expressions of D44V6 and CXCR4 in 200 paraffin-embeded thyoid carcinoma tissues(with lymph node metastasis in 100) and 20 thyroid adenoma were studied by imrnunochemical envison method. Results Positive expressions of CD44v6 and CXCR4 in the group of thyoid carcinoma were 72% and 690/6, respectively, which were significantly higher than those in the group of thyroid adenoma(20% and 15%). Positive expressions of CD44v6 and CXCR4 in the group of thyoid carcinoma with lymph node involvement were 88% and 91%, respectively, which were significantly higher than those in the group of thyoid carcinoma without lymph node involvement(56 % and 47%). In different pathocategory, clinical stage and life span, the positive expressions of CD44v6 and CXCR4 were significantly different. Conclusion The results suggest that CD44v6 and CXCR4 can be regarded as the valuable molecular markers for making identification of the benign tumors and judging the carcinoma with or without lymph node metastasis and predicting the prognosis.
出处
《江苏医药》
CAS
CSCD
北大核心
2008年第7期659-661,F0002,共4页
Jiangsu Medical Journal